Records containing: Medullary Thyroid Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-16A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
-
CLINICAL_TRIALS study record update · 2026-04-09Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
-
CLINICAL_TRIALS study record update · 2026-03-27Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma
-
CLINICAL_TRIALS study record update · 2026-01-06A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
-
CLINICAL_TRIALS study record update · 2025-11-18Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-10-09RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3
-
CLINICAL_TRIALS study record update · 2025-09-02A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
-
CLINICAL_TRIALS study record update · 2025-06-24Prospective, Single-centre, Feasibility Study to Evaluate the Use of 18F-PSMA PET/CT in Patients With Biochemically Active Medullary Thyroid Cancer
-
CLINICAL_TRIALS study record update · 2025-05-31A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-04-30Ultrasound Guided Percutaneous Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
-
CLINICAL_TRIALS study record update · 2025-01-17Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
-
CLINICAL_TRIALS study record update · 2025-01-03Predective Factors for Tumor Aggressiveness in Medullary Thyroid Cancer
-
CLINICAL_TRIALS study record update · 2024-07-26Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
-
CLINICAL_TRIALS study record update · 2024-06-13A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
-
CLINICAL_TRIALS study record update · 2024-06-13A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
-
CLINICAL_TRIALS study record update · 2024-02-26Evaluating the Clinical Value of 68Ga-TCR-FAPI PET/CT to Guide the Surgical Treatment for Medullary Thyroid Carcinoma (MTC)
-
CLINICAL_TRIALS study record update · 2024-02-06Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
-
CLINICAL_TRIALS study record update · 2024-01-30A Phase I/II Study of Oral TY-1091 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, RET-Mutation Medullary Thyroid Cancer, and Other Tumors With RET Alterations
-
CLINICAL_TRIALS study record update · 2024-01-05A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.
-
CLINICAL_TRIALS study record update · 2023-10-12Analyzing the Patterns of Patient Engagement and Trends in Participation Observed in Medullary Thyroid Cancer Clinical Trials
-
CLINICAL_TRIALS study record update · 2023-07-25A Real World Study of Anlotinib for Patients With Advanced Medullary Thyroid Carcinoma
-
CLINICAL_TRIALS study record update · 2023-04-12A Phase I/II, Open-Label, Single-arm, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.
-
CLINICAL_TRIALS study record update · 2022-08-31Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
-
CLINICAL_TRIALS study record update · 2022-06-02A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
-
CLINICAL_TRIALS study record update · 2021-10-13A Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer (MTC)